Posts

Featured Post

TikTok x Blossom AI Hackathon Brings Together Saudi Arabia's Emerging Entrepreneurs and Innovators

-
Image
    TikTok and Blossom Accelerator successfully hosted an AI hackathon that brought together together aspiring entrepreneurs, students, researchers, developers, and AI enthusiasts from across Saudi Arabia for an intensive innovation challenge focused on developing artificial intelligence-driven solutions to real-world challenges.   The initiative reflects a shared commitment to fostering innovation, entrepreneurship, and digital skills development while supporting Saudi Arabia’s rapidly growing AI ecosystem.   The hackathon attracted 63 projects, with participants collaborating in teams to develop AI-powered solutions and innovative concepts with the potential to address real-world opportunities and challenges across a range of sectors. A panel of industry experts evaluated the projects based on innovation, technical execution, scalability, and potential real-world impact. The full-day hackathon was designed to transform promising ideas into testable prototypes...
للمزيد »

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026

-
Image
 Three million prescriptions for Wegovy® pill since launch on January 5th serve as another milestone in one of the strongest US pharmaceutical launches by volume on record1  The majority of new Wegovy® pill prescriptions are for people new to GLP-1 therapy, bringing obesity medicine to many previously untreated1  This news comes as Novo Nordisk has a large presence at the American Diabetes Association’s 2026 Scientific Sessions, including a variety of Wegovy® analyses in adults with obesity    Novo Nordisk today announced Wegovy® (semaglutide) tablets 25 mg have surpassed three million prescriptions in just over five months, establishing Wegovy® pill as one of the strongest US pharmaceutical launches by volume on record.¹ The three million milestone corresponds to one prescription filled roughly every five seconds, reflecting continued uptake since Wegovy® pill became available in January 2026. Further underscoring its rapid adoption, Wegovy® pill reached its in...
للمزيد »

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

-
Image
    The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries - showed that cardiovascular (CV) inflammation remains highly prevalent among people with cardiovascular disease (CVD), despite current standard of care treatment1,2   In fact, two in five people with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), or heart failure, have CV inflammation1,2   This matters because CV inflammation is an independent risk factor for CV events, such as heart attack and stroke, in people living with CVD. In line with ESC guidelines & ACC scientific statement, this calls for action on the importance of measuring hsCRP in CVD patients3, 13, 14, 15   Novo Nordisk today presented new results from the landmark POSEIDON real-world evidence study at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece. The study showed that CV inflammation remains highly prevalent among people with CVD ...
للمزيد »

Wegovy®️ pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

-
Image
              With a mean weight loss of 16.6%[1], Wegovy®️ pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP 1 treatment recommended by CHMP for weight management in the EU .           CHMP recommends Wegovy®️ pill for approval to reduce excess body weight and maintain long-term weight reduction. The recommendation also includes data from SELECT which demonstrates that Wegovy®️ reduces the risk of major adverse cardiovascular events (MACE)*, in the label           Wegovy®️ pill is the only oral GLP-1 treatment with no drug-drug restrictions in the label           Novo Nordisk plans to launch Wegovy®️ pill in select markets outside the US in the second half of 2026     Novo Nordisk today announced that the Committee for Medicinal Products for Human...
للمزيد »